Ofloxacin Tablets

This product is a DNA helicase inhibitor, which has strong antibacterial effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. There is no cross-resistance between this product and other types of antibacterial drugs.

Ofloxacin

This product is off-white tablets, odorless and bitter.

It is mainly used for acute and chronic bacterial infections of urinary, reproductive, digestive, respiratory systems, skin, soft tissues, etc. caused by sensitive bacteria. It includes patients in internal medicine, surgery, urology, obstetrics and gynecology, ophthalmology, otolaryngology, dermatology, etc.

Oral administration: Adults: 0.2-0.3g at a time, twice a day or as directed by a doctor.

Nausea, vomiting, stomach and abdominal discomfort, insomnia, dizziness, headache, rash and increased serum alanine aminotransferase may occur occasionally, but they are generally tolerated and disappear after drug discontinuation.

It should not be used by people who are allergic to quinolones, children, pregnant and lactating women, and patients with epilepsy.

Precautions for children: The safety of this product in infants and adolescents under 18 years of age has not been determined. However, this product can cause joint lesions when used in several young animals. Therefore, it should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women, and lactating women should suspend breastfeeding when using this product. Precautions for the elderly: Elderly patients often have impaired renal function, and since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. This product has little effect on the metabolism of theophylline, but the blood concentration of theophylline should still be measured and the dosage adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should also be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increase in the blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (t1/2), and may cause central nervous system toxicity.

Keep in airtight container and away from light.

0.1g

Tentative two years